Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Er lotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2): 123-132, 2005.
Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652): 1809-1818, 2008.
Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or car boplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10): 947-957, 2009.
Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJT0G3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2): 121-128, 2010.
Cappuzzo F, Cliuleanu T, Stelmakh L, et al: SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27 (15S): abstr 8001, 2009.